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Acute mucositis is one of the main severe 
toxicities that occur during and early af-
ter concurrent chemotherapy and radio-
therapy [1, 2, 3, 4, 5, 6, 7]. On average, be-
tween 20% and 30% of patients will suffer 
from grade 3–4 acute oesophagitis, which 
requires tube or intravenous (i.v.) feeding. 
At present, no effective treatments other 
than symptomatic are of proven value [8, 
9, 10].
Prognostic factors that are associated 
with acute radiation-induced oesophagi-
tis include the overall treatment time of 
radiotherapy, twice-daily fractionation, 
mean and maximal oesophageal dose, the 
volume of the oesophagus that receives a 
certain dose such as the V55, and by far 
the most important the concurrent ad-
ministration of chemotherapy with ra-
diotherapy [11, 12, 13, 14, 15].
In an earlier study, we found that not 
the dose of chemotherapy was correlat-
ed with radiation-induced oesophagitis 
in concurrent schedules, but the level of 
neutropenia [16]. Patients with grade 4 
neutropenia had an odds ratio of about 
20 to develop grade 3 oesophagitis. The 
grade of neutropenia was an independent 
prognostic factor together with the mean 
oesophageal dose for the development of 
acute oesophagitis. We hypothesized that 
the level of neutropenia was a surrogate 
for the biological dose of chemotherapy. 
However, it could not be ruled out that 
the genotype/phenotype that is related to 
susceptibility for chemotherapy-induced 
neutropenia would also be associated with 
a higher radiosensitivity of the oesopha-
gus.
We therefore investigated the associa-
tion between neutropenia during induc-
tion chemotherapy and the development 
of acute radiation-induced during or after 
subsequent radiotherapy. For comparison, 
patients treated with concurrent chemo-
radiotherapy were also studied.
Patients and methods
Patients and treatment
Between February 1, 2006 and Septem-
ber 30, 2008, 119 patients were prospec-
tively included in the two institutions the 
Maastro Clinic in Maastricht, The Nether-
lands, and the University Hospital Ghent, 
Belgium.
The concurrent group comprised
F		34 patients with stage I–III small cell 
lung cancer from the Maastro Clin-
ic treated with concurrent carbop-
latin and etoposide and concurrent 
chest irradiation to a dose of 45 Gy in 
30 twice-daily fractions in 3 weeks as 
previously described [17], and
F		36 patients with stage III non-
small lung cancer (NSCLC) treat-
ed in Ghent with concurrent cisplat-
in and etoposide (75 mg/m2 day 1 and 
100 mg/m2 i.v. on days 1–3, respec-
tively, every 3 weeks for three cycles) 
and radiotherapy to a dose of 66 Gy 
in once-daily fractions of 2 Gy, 5 days 
per week.
The sequential group comprised
F		49 patients with stage III NSCLC 
treated in Ghent with sequential cis-
platin and gemcitabine (75 mg/m2 
day 1 and 1,000 mg/m2 i.v. on days 1 
and 8, respectively, every 3 weeks for 
three cycles) and radiotherapy to a 
dose of 66 Gy in once-daily fractions 
of 2 Gy, 5 days per week.
Radiotherapy dose specification was done 
according to ICRU 50 recommendations 
[18].
Patients were seen by the pulmonolo-
gist and by the radiation oncologist be-
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fore treatment and by one of them week-
ly during therapy, the first few weeks af-
ter the end of treatment until the acute 
side-effects resolved to grade 1, and there-
after every 3 months the first 2 years, ev-
ery 6 months from years 3–5 and every 
year after 5 years. Before and weekly dur-
ing chemotherapy or radiotherapy, white 
blood cells and the percentage of neu-
trophilic granulocytes were measured as 
specified by the standard protocol during 
the inclusion period.
Oesophageal toxicity was scored by the 
treating physician using the CTCAE3.0 
(Common Terminology Criteria for Ad-
verse Events, Version 3.0) criteria.
Results are expressed as mean ± stan-
dard deviation (SD) and their range. Dif-
ferences between continuous variables 
were calculated with Wilcoxon’s signed 
rank test and between proportions by a 
χ2 test. An ordinal regression analysis was 
used to correlate the grade of neutrope-
nia with oesophagitis grade 3 (G3). The 
odds ratio of oesophageal G3 toxicity ver-
sus neutropenia was calculated as (a/b)/
(c/d) where a, b, c and d are the numbers 
of patients according to the frequency ta-
ble (.	Tab. 1).
Results
A total of 119 patients were included; 
63% were male. In the sequential group 
(n=49), the mean age was 67.1±8.0 years 
(range 49–83), the mean radiation dose 
64.0±10.1 Gy (range 30–70), the mean 
overall treatment time (OTT) of radio-
therapy 43.8±13.6 days (range 16–57), and 
the mean of the mean esophageal dose 
(MED) 21.5±11.4 Gy (range 2.7–43.7). In 
the concurrent group (n=70), the mean 
age was 60.4±8.7 years (range 42–81), 
the mean radiation dose 52.1±9.0 Gy 
(range 45–70), the mean OTT of radio-
therapy 32.8±11.3 days (range 45–70) 
and the mean MED 25.5±7.3 Gy (range 
6.0–45.4). The OTT was shorter in the 
twice a day vs. the once a day concur-
rent group (23.6±6.1 days (range 18–
45 days) vs. 41.6±7.3 days (range 23–
51 days); p<0.001). Only the mean MED 
was not significantly different between 
the concurrent and the sequential groups 
(p=0.15), whereas all other differences 
were significant at a p level<0.001.
The oesophageal toxicities in the con-
current group were grade 0 (G0): 4 (5.7%), 
G1: 17 (24.3%), G2: 32 (45.7%), G3: 17 
(24.3%) and in the sequential group G0: 
17 (34.6%), G1: 30 (61.2%), G2: 1 (2.1%), 
G3: 1 (2.1%). These differences are signif-
icant (p<0.001).
Neutropenia in the concurrent group 
during chemoradiotherapy was very fre-
quent: G0: 1 (1.4%), G1: 8 (11.4%), G2: 13 
(18.6%), G3: 19 (27.1%), G4: 29 (41.4%). 
Neutropenia in the patients receiving se-
quential chemoradiotherapy was dur-
ing induction chemotherapy: G0: 4 
(8.2%), G1: 3 (6.1%), G2: 11 (22.4%), G3: 16 
(32.7%), G4: 15 (30.6%). Patients receiving 
concurrent chemotherapy and radiother-
apy did not have significantly more severe 
(grade 3+4) neutropenia during their in-
duction phase than those during sequen-
tial chemotherapy and radiation (68.5% 
vs. 63.2%, p=0.54).
During radiotherapy, however, neutro-
penia was hardly observed in patients who 
received sequential chemoradiation, with 
only 2 individuals (4%) with only grade 1 
neutropenia. In this patient group, the 
mean day to develop maximal neutrope-
nia was −52±25.4 (range −163 to −8) days 
before the beginning of radiotherapy (the 
first day of radiotherapy being defined as 
day 1). Maximal oesophagitis developed 
after a mean of 23.8±11.8 (range 5–48) 
days after the start of radiotherapy.
In the concurrent group, the odds ra-
tios (OR) of grade 3 oesophagitis vs. neu-
tropenia were as follows: G2 vs. G0/1: 5.60 
(95% confidence interval (CI) 1.55–20.26), 
p=0.009; G3 vs. G0/1: 10.40 (95% CI 3.19–
33.95); p=0.0001; G4 vs. G0/1: 12.60 (95% 
CI 4.36–36.43); p<0.00001 (.	Fig. 1).
There was no correlation between the 
occurrence of neutropenia during induc-
tion chemotherapy and acute oesopha-
gitis during or after radiotherapy alone 
(.	Tab. 2).
In a univariate analysis, total radia-
tion dose (p<0.001), overall treatment 
time of radiotherapy (p<0.001), mean oe-
sophageal dose (p=0.038) and neutrope-
nia (p<0.001) were significantly associated 
with the development of oesophagitis. In a 
multivariate analysis, only neutropenia re-
mained significant (p=0.023).
Discussion
In this series, we confirm that neutrope-
nia is a very important parameter that is 
associated with the development of se-
vere oesophagitis during or after con-
current chemoradiotherapy [16]. Patients 
who received sequential chemotherapy 
and radiotherapy had the same incidence 
of severe neutropenia during their induc-
tion phase as individuals who were treated 
with concurrent chemoradiation. Howev-
er, they did not develop severe oesophagi-
tis when irradiated later. It may be argued 
that the incidence of oesophagitis was 
very low in the patient group that received 
sequential chemotherapy and radiother-
apy. However, their total radiation dose, 
overall treatment time and MED was in 
the expected range. The MED, which was 
according to literature and also in our se-
Tab. 1 Frequency table for Neutropenia and Oesophagitis Grade 3
  Oesophagitis Grade 3
Neutrophenia Present Not present
High grade a b
Low grade c d
Tab. 2 Sequential chemotherapy and radiotherapy group: neutropenia before radiotherapy 
during induction chemotherapy vs. maximal oesophagitis during or after radiotherapy
Neutropenia Oesophageal toxicity grade 1–3
  Number Percent
Grade 0 2/4 50
Grade 1 2/3 66
Grade 2 7/11 64
Grade 3 10/16 63
Grade 4 8/15 53
None of the differences are significant.
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ries highly associated with oesophagitis, 
was not significantly different between the 
sequential and concurrent groups [1, 2, 3, 
4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]. The inci-
dence and severity of oesophagitis and of 
neutropenia in the chemoradiation group 
are also in line with published data [2, 3, 
4, 15, 19].
The finding that neutropenia induced 
by chemotherapy before radiotherapy was 
not associated with oesophagitis during 
radiotherapy implies that the correlation 
between neutropenia and acute oesoph-
agitis during concurrent chemoradiation 
may be either due to a higher effective bio­
Abstract · Zusammenfassung




Radiation-induced oesophagitis in lung cancer patients. Is susceptibility for neutropenia a risk factor?
Abstract
Background. Radiation-induced oesopha-
gitis is a major side effect of concurrent che-
motherapy and radiotherapy. A strong asso-
ciation between neutropenia and oesopha-
gitis was previously shown, but external vali-
dation and further elucidation of the possible 
mechanisms are lacking.
Methods and patients. A total of 119 pa-
tients were included at two institutions. The 
concurrent group comprised 34 SCLC pa-
tients treated with concurrent carboplatin 
and etoposide, and concurrent chest irradia-
tion, and 36 NSCLC patients with concurrent 
cisplatin and etoposide, and concurrent ra-
diotherapy, while the sequential group com-
prised 49 NSCLC patients received sequential 
cisplatin and gemcitabine, and radiotherapy.
Results. Severe neutropenia was very fre-
quent during concurrent chemoradiation 
(grade: 4 41.4%) and during induction che-
motherapy in sequentially treated patients 
(grade 4: 30.6%), but not during radiotherapy 
(only 4% grade 1). In the concurrent group, 
the odds ratios of grade 3 oesophagitis vs. 
neutropenia were the following: grade 2 vs. 
grade 0/1: 5.60 (95% CI 1.55–20.26), p=0.009; 
grade 3 vs. grade 0/1: 10.40 (95% CI 3.19–
33.95); p=0.0001; grade 4 vs. grade 0/1: 12.60 
(95% CI 4.36–36.43); p<0.00001. There was 
no correlation between the occurrence of 
neutropenia during induction chemothera-
py and acute oesophagitis during or after ra-
diotherapy alone. In the univariate analysis, 
total radiation dose (p<0.001), overall treat-
ment time of radiotherapy (p<0.001), mean 
oesoph ageal dose (p=0.038) and neutro-
penia (p<0.001) were significantly associat-
ed with the development of oesophagitis. In 
a multivariate analysis, only neutropenia re-
mained significant (p=0.023).
Conclusion. We confirm that neutropenia 
is independently correlated with oesopha-
gitis in concurrent chemoradiation, but that 
the susceptibility for chemotherapy-induced 
neutropenia is not associated with radiation-
induced oesophagitis. Further studies focus-
ing on the underlying mechanisms are thus 
warranted.
Keywords
Oesophagitis · Dysphagia · Radiotherapy · 
Lung cancer · Toxicity
Bestrahlungsinduzierte Ösophagitis bei Lungenkrebspatien-
ten. Ist Anfälligkeit für Neutropenie ein Risikofaktor?
Zusammenfassung
Hintergrund. Eine durch Bestrahlung indu-
zierte Ösophagitis ist eine Hauptnebenwir-
kung bei gleichzeitig durchgeführter Chemo- 
und Strahlentherapie. Ein enger Zusammen-
hang von Neutropenie und Ösophagitis wur-
de bereits früher nachgewiesen, eine exter-
ne Bestätigung und eine weiterführende Er-
gründung der zugrundeliegenden Mechanis-
men fehlen aber noch.
Methoden und Patienten. 119 Patien-
ten aus zwei Einrichtungen wurden in die-
se Studie aufgenommen. Die Gruppe mit si-
multaner Strahlen- und Chemotherapie be-
stand aus 34 SCLC-Patienten, die gleichzei-
tig mit Carboplantin, Etoposid und einer 
Brustbestrahlung behandelt wurden sowie 
aus 36 NSCLC-Patienten, die gleichzeitig Cis-
platin und Etoposid und eine Strahlenthe-
rapie erhielten. In der anderen Gruppe folg-
ten die Behandlungsschritte nacheinander. 
Hier bekamen 49 NSCLC-Patienten Cispla-
tin und Gemcitabin in Folge plus eine Strah-
lentherapie.
Ergebnisse. Eine schwere Neutropenie trat 
sehr häufig während gleichzeitiger Chemo-
bestrahlung (Grad: 4 41,4%) und während 
der Induktions-Chemotherapie bei aufeinan-
derfolgend behandelten Patienten (Grad 4: 
30,6%) auf, nicht aber während der Strah-
lentherapie (nur 4% Grad 1). In der gleich-
zeitig behandelten Gruppe waren die Odds 
Ratios von Stufe 3 Ösophagitis vs. Neutrop-
enie folgendermaßen: Grad 2 vs. Grad 0/1: 
5,60 (95%-KI 1,55–20,26), p=0,009; Grad 3 
vs. Grad 0/1: 10,40 (95%-KI 3,19–33,95), 
p=0,0001; Grad 4 vs. Grad 0/1: 12,60 (95%-
KI 4,36–36,43), p<0,00001. Es gab keine Kor-
relation zwischen dem Auftreten von Neu-
tropenie während der Induktions-Chemothe-
rapie und akuter Ösophagitis während oder 
nach alleiniger Strahlentherapie. In einer uni-
variablen Analyse waren die totale Bestrah-
lungsdosis (p<0,001), die gesamte Behand-
lungsdauer der Strahlentherapie (p<0,001), 
die durchschnittliche ösophageale Dosis 
(p=0,038) und die Neutropenie (p<0,001) er-
heblich mit der Entwicklung einer Ösopha-
gitis verknüpft. In einer multivariablen Ana-
lyse blieb nur die Neutropenie signifikant 
(p=0,023).
Schlussfolgerung. Wir bestätigen, dass bei 
gleichzeitiger Chemobestrahlung, Neutro-
penie mit Ösophagitis unabhängig korreliert 
ist, aber die Anfälligkeit für eine durch Che-
motherapie induzierte Neutropenie nicht mit 
 einer durch Bestrahlung induzierten Ösopha-
gitis verknüpft ist. Weiterführende Studien, 
die sich auf die zugrundeliegenden Mecha-
nismen konzentrieren, sind lohnend.
Schlüsselwörter
Ösophagitis · Dysphagie · Strahlentherapie · 
Lungenkrebs · Toxizität
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logical chemotherapy dose which causes 
more cell kill and hence more toxicity 
and/or to a higher susceptibility for local 
infections (e.g. candidiasis) of the oesoph-
agus. If it would be known which micro-
organisms are surinfecting radiation-in-
duced oesophageal lesions, only the 60% 
of patients with grade 3 or more neutrope-
nia could receive prophylactic antibiotics 
and/or anti-mycotic drugs that could de-
crease symptoms, tube feeding and hospi-
tal admissions. An early non-randomised 
study suggests that the prophylactic use of 
amphotericin B may indeed be beneficial 
[10]. However, it remains to be investigat-
ed whether this treatment could indeed 
reduce the incidence of severe oesopha-
gitis, i.e. grade 3–4. This would allow in-
creasing the quality of life of patients [20] 
and decreasing in-patient care and costs. 
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Fig. 1 9 Concurrent 
group. Odds ratios for 
developing oesopha-
gitis grade 3 (G3) as a 
function of the grade 
of neutropenia
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